Olema Pharmaceuticals (OLMA) Total Current Liabilities (2020 - 2026)
Olema Pharmaceuticals (OLMA) posted quarterly Total Current Liabilities of $47.2 million for Q1 2026, up 80.97% year-over-year from $26.1 million in Q1 2025, and down 8.95% quarter-over-quarter from $51.8 million in Q4 2025.
Olema Pharmaceuticals (OLMA) Total Current Liabilities (2020 - 2026) Analysis & Trends
Olema Pharmaceuticals (OLMA) has reported Total Current Liabilities for 7 consecutive years, with $47.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities rose 80.97% year-over-year to $47.2 million; the TTM figure through Mar 2026 stood at $47.2 million (up 80.97% YoY), while the FY2025 annual figure was $51.8 million, up 24.05% from the prior year.
- Total Current Liabilities fell to $47.2 million in Q1 2026 per OLMA's latest filing, from $51.8 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $51.8 million in Q4 2025 and bottomed at $117000.0 in Q1 2022.
- Historically, Total Current Liabilities has averaged $25.8 million across 5 years, with a median of $26.1 million in 2025.
- Annual changes were most pronounced in 2023 — Total Current Liabilities soared 16489.74% — and 2025, when it retreated 0.61%.
- Olema Pharmaceuticals' Total Current Liabilities stood at $16.5 million in 2022, then jumped by 30.65% to $21.6 million in 2023, then soared by 93.14% to $41.8 million in 2024, then climbed by 24.05% to $51.8 million in 2025, then decreased by 8.95% to $47.2 million in 2026.
- Business Quant data shows OLMA's Total Current Liabilities at $47.2 million in Q1 2026, $51.8 million in Q4 2025, and $41.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Olema Pharmaceuticals | 930.10 Mn | 930.10 Mn | - | 53.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 53.01 Mn |
| Mar 31, 2026 | 47.17 Mn |
| Dec 31, 2025 | 51.80 Mn |
| Sep 30, 2025 | 41.66 Mn |
| Jun 30, 2025 | 33.16 Mn |
| Mar 31, 2025 | 26.06 Mn |
| Dec 31, 2024 | 41.76 Mn |
| Sep 30, 2024 | 30.70 Mn |
| Jun 30, 2024 | 26.54 Mn |
| Mar 31, 2024 | 26.22 Mn |
| Dec 31, 2023 | 21.62 Mn |
| Sep 30, 2023 | 15.97 Mn |
| Jun 30, 2023 | 14.83 Mn |
| Mar 31, 2023 | 19.41 Mn |
| Dec 31, 2022 | 16.55 Mn |
| Sep 30, 2022 | 12.55 Mn |
| Jun 30, 2022 | 12.31 Mn |
| Mar 31, 2022 | 117,000.00 |
| Dec 31, 2021 | 172,000.00 |
| Sep 30, 2021 | 8.90 Mn |